Categories
Tags
Authors: Ponti G, Roli L, Oliva G, Manfredini M, Trenti T, Kaleci S et al. doi: https://doi.org/10.1515/cclm-2021-0168 Abstract The Covid-19 pandemic is a global challenge, with rapidly increasing cases from the high infective aetiological agent, the Covid-19 virus. In October 2020, over 48 million confirmed Covid-19 cases and one million deaths were confirmed (www.who.int). There [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19, Homocysteine
Authors: Geerts M, de Greef BT, Sopacua M, Faber CG PMID: 33766992 PMCID: PMC8205474 DOI: 10.1212/WNL.0000000000011919 Abstract Objective: This is the first double-blind randomized controlled trial evaluating the efficacy and safety of IV immunoglobulin (IVIG) vs placebo in patients with idiopathic small fiber neuropathy (I-SFN). Methods: Between July 2016 and November 2018, 60 Dutch patients [...]
Categories: I-RECOVER Post-Vaccine
Authors: Classen JB Abstract Many have argued that the outbreak of COVID-19 is the result of the release of a viral based bioweapon. Vaccines to COVID-19 have been developed and a policy of universal immunization has been initiated with total disregard to the fact that the virus may be a bioweapon. The potential risk [...]
Categories: I-RECOVER Post-Vaccine
Authors: Idrees D, Kumar V PMID: 33789211 PMCID: PMC7988450 DOI: 10.1016/j.bbrc.2021.03.100 Abstract The post-infection of COVID-19 includes a myriad of neurologic symptoms including neurodegeneration. Protein aggregation in brain can be considered as one of the important reasons behind the neurodegeneration. SARS-CoV-2 Spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) binds to heparin and heparin [...]
Categories: I-RECOVER Post-Vaccine
Tags: Neurodegeneration, SARS-CoV-2, Spike Protein
Authors: Patidar GK, Land KJ, Vrielink H, Dann EJ, Spitalnik SL PMID: 33730761 PMCID: PMC8250601 DOI: 10.1111/vox.13067 Abstract Background and objectives: Cytokine release syndrome in COVID-19 is due to a pathological inflammatory response of raised cytokines. Removal of these cytokines by therapeutic plasma exchange (TPE) prior to end-organ damage may improve clinical outcomes. This manuscript [...]
Categories: I-RECOVER Post-Vaccine
Authors: Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB PMID: 33683290 PMCID: PMC7941251 doi:10.1001/jama.2021.3976 Abstract Anaphylaxis to the mRNA COVID-19 vaccines is currently estimated to occur in 2.5 to 11.1 cases per 1 million doses, largely in individuals with a history of allergy.1 Allergic concerns contribute to vaccine hesitancy; we [...]
Categories: I-RECOVER Post-Vaccine
Authors: Hengartner MP, Amendola S, Kaminski JA PMID: 33685964 DOI: 10.1136/jech-2020-214611 Abstract Background: There is ongoing controversy whether antidepressant use alters suicide risk in adults with depression and other treatment indications. Methods: Systematic review of observational studies, searching MEDLINE, PsycINFO, Web of Science, PsycARTICLES and SCOPUS for case-control and cohort studies. We included studies on [...]
Categories: I-RECOVER Post-Vaccine
Authors: Pitt B, Sutton NR, Wang Z, Holinstat M PMID: 33667455 PMCID: PMC7923868 DOI: 10.1016/j.ejphar.2021.173988 Abstract There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a [...]
Categories: I-RECOVER Long Covid, I-RECOVER Post-Vaccine
Tags: COVID-19, Valproic Acid
Authors: Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR PMID: 33330894 PMCID: PMC7743105 DOI: 10.1101/2020.12.10.20247205 Abstract COVID-19 manifests with a wide spectrum of clinical phenotypes that are characterized by exaggerated and misdirected host immune responses1-8. While pathological innate immune activation is well documented in severe disease1, the impact of autoantibodies on [...]
Categories: I-RECOVER Post-Vaccine
Tags: autoantibodies, COVID-19
Authors: Li G, Wu Z, Shang J, Xie Z, Chen C, Zhang C PMID: 33524789 DOI: 10.1016/j.biopha.2021.111286 Abstract Metformin is the first-line option for treating newly diagnosed diabetic patients and also involved in other pharmacological actions, including antitumor effect, anti-aging effect, polycystic ovarian syndrome prevention, cardiovascular action, and neuroprotective effect, etc. However, the mechanisms of [...]
Categories: I-RECOVER Post-Vaccine